FDA Expands At-Home Leqembi Dosing for Early Alzheimer’s

What Did the FDA Approve for At-Home Leqembi Treatment?

Leqembi, known generically as lecanemab, is a monoclonal antibody that targets aggregated forms of amyloid beta in the brain. The new approval extends at-home administration to the beginning of treatment, potentially reducing dependence on infusion centers and making the therapy more practical for some patients and caregivers.

The authorization changes how the medicine can be delivered, not who should receive it. Leqembi is intended for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease whose amyloid pathology has been confirmed. It has not been established as a treatment for moderate or advanced dementia, and it does not restore memory already lost.

How Does Lecanemab Affect Early Alzheimer’s Disease?

The phase 3 Clarity AD trial enrolled people with early Alzheimer’s disease and confirmed brain amyloid. Published in The New England Journal of Medicine, the trial found that lecanemab reduced amyloid burden and produced a statistically significant but clinically modest slowing of decline over 18 months compared with placebo.

Lecanemab binds preferentially to soluble amyloid-beta aggregates and promotes their removal through immune mechanisms. Amyloid is only one component of Alzheimer’s biology, however; tau accumulation, inflammation, vascular injury and neuronal loss also contribute. Patients and families therefore need realistic counseling about the expected benefit and the continued need for supportive care.

What Safety Monitoring Is Needed With At-Home Leqembi?

Leqembi carries a boxed warning for amyloid-related imaging abnormalities, or ARIA. These changes may involve temporary brain swelling or small areas of bleeding and are often detected on MRI before symptoms develop. When symptoms occur, they can include headache, confusion, dizziness, visual disturbance, nausea, weakness or seizures; serious and occasionally fatal events have been reported.

People carrying two copies of the APOE ε4 gene have a higher risk of ARIA, and the FDA prescribing information recommends discussing genetic testing before treatment. Clinicians must also consider anticoagulant use, existing brain microbleeds and other cerebrovascular risks. Patients receiving injections at home still need access to an experienced Alzheimer’s treatment team and urgent assessment if neurological symptoms appear.